This week in therapeutics

Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Infectious disease

Viral infection

Not applicable

In vitro and mouse studies identified membrane-intercalating photosensitizers that could help treat viral infections. In vitro studies showed that the previously identified viral fusion inhibitor LJ001 is a light-activated, membrane-intercalating photosensitizer that catalyzes the oxidation of unsaturated phospholipids in viral membranes. Follow-up SAR studies led to the identification of oxazolidine-2,4-dithiones with 100-fold increases for in vitro potency and 10- to 100-fold increases in bioavailability over LJ001. In mice challenged with a lethal dose of Rift Valley fever virus, two of the three lead oxazolidine-2,4-dithiones increased survival times compared with no treatment. Next steps could include testing the lead oxazolidine-2,4-dithiones in additional models for viral infection (see Lou, K.-J., SciBX 3(8);
doi:10.1038/scibx.2010.235).

SciBX 619); doi:10.1038/scibx.2013.471
Published online May 16, 2013

Patent application filed; licensing status unavailable

Vigant, F. et al. PLoS Pathog.; published online April 18, 2013;
doi:10.1371/journal.ppat.1003297
Contact: Benhur Lee, University of California, Los Angeles, Calif.
e-mail:
bleebhl@ucla.edu